Severe clinical course of de novo hepatitis B infection after liver transplantation.

The aim of this study is to determine the origin, clinical outcome, allograft histological characteristics, and virological outcome of de novo hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT). We studied 136 hepatitis B surface antigen (HBsAg)-negative liver transplant recipients. HBV DNA was detected by dot-blot hybridization and polymerase chain reaction (PCR). The S gene was sequenced. Hepatitis C virus (HCV) RNA was assessed by PCR. The long-term clinical and histological outcome was determined. Six of 136 HBsAg-negative patients (4.4%) became HBsAg positive after transplantation. The source of HBV infection was reactivation of latent HBV infection in 2 patients and was not identified in 4 patients. Two donors had isolated core antibody. Two of these 6 patients developed acute liver failure related to hepatitis B. The 4 other patients had severe chronic hepatitis related to hepatitis B. All patients had high-level HBV replication. No significant mutations in the S gene were found. These data suggest that de novo hepatitis B infection is not a mild disease and might represent a significant cause of graft dysfunction. This is the first report of fulminant hepatitis caused by de novo hepatitis B infection after OLT.

[1]  A. El-Kadi,et al.  Cytochrome P-450 content and activity after cold storage of rat hepatocytes in university of wisconsin and sodium-lactobionate-sucrose solutions. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  D. Snydman,et al.  Organ donor screening for infectious diseases: review of practice and implications for transplantation. , 1998, Transplantation.

[3]  G. Klintmalm,et al.  De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. , 1998, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  T. Pruett.  Editorial response: De novo HBV infections after liver transplantation. , 1998, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  R. D. de Man,et al.  Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. , 2008, Liver.

[6]  R. Wiesner,et al.  Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. , 1997, Gastroenterology.

[7]  J. Crespo,et al.  Hepatitis C virus recurrence after liver transplantation: relationship to anti-HCV core IgM, genotype, and level of viremia. , 1997, The American journal of gastroenterology.

[8]  Y. Ilan,et al.  Natural course of de novo hepatitis B virus infection in liver transplant recipients. , 1997, Transplantation proceedings.

[9]  S. Günther,et al.  Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. , 1997, Journal of hepatology.

[10]  D. Samuel,et al.  De novo and apparent de novo hepatitis B virus infection after liver transplantation. , 1997, Journal of hepatology.

[11]  S. Caldwell.  Hard times and imperfect organs. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  R. Wiesner,et al.  The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[13]  R. Tur-kaspa,et al.  Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. , 1997, Transplantation.

[14]  E. Keeffe,et al.  Liver transplantation in Asian patients with chronic hepatitis B , 1997, Hepatology.

[15]  M. Vivarelli,et al.  De Novo Hepatitis B and C Viral Infection after Liver Transplantation , 1997, World Journal of Surgery.

[16]  D. Tyrrell,et al.  Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. , 1996, Transplantation.

[17]  Y. Chen,et al.  De novo hepatitis B virus infection after orthotopic liver transplantation. , 1996, Transplantation proceedings.

[18]  E. Keeffe,et al.  Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. , 1995, Journal of hepatology.

[19]  H. Schlicht,et al.  Liver transplantation and de novo hepatitis B Infection , 1994, The Lancet.

[20]  L. Ferrell,et al.  "Occult" hepatitis B virus as source of infection in liver transplant recipients , 1994, The Lancet.

[21]  M. Lucey,et al.  Hepatitis B infection and liver transplantation: The art of the possible , 1994, Hepatology.

[22]  G. Alexander,et al.  Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.

[23]  C. Chu,et al.  Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. , 1992, The Journal of infectious diseases.

[24]  D. V. van Thiel,et al.  Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease , 1991, Hepatology.

[25]  R Williams,et al.  Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis , 1991, Hepatology.

[26]  S. Kwok,et al.  Avoiding false positives with PCR , 1989, Nature.

[27]  R. Burk,et al.  Hepatitis B virus DNA contains a glucocorticoid-responsive element. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[28]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[29]  F. Perrycoste.  Belladonna Plaister for Bee-Stings , 1911, Nature.